Important differences between human and mouse APOE gene promoters: Limitation of mouse APOE model in studying Alzheimer's disease

Journal of Neurochemistry

Volumn 103, Issue 3, 2007, Pages 1237-1257

  Maloney, Bryan ^a   Ge, Yuan Wen ^a   Alley, George M ^a   Lahiri, Debomoy K ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aging; Amyloid; Brain; Cholesterol; Gene regulation; Glia; Lipid; Neuron; Nuclear factor; Promoter; Transcription

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E EPSILON 4; GENE PRODUCT; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; ASTROCYTE; BRAIN NERVE CELL; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; GENE EXPRESSION REGULATION; GENE SEQUENCE; GLIA CELL; HUMAN; HUMAN CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA INTERACTION; PROTEIN FUNCTION; PROTEIN VARIANT; RAT; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; SOUTHWESTERN BLOTTING; SPECIES DIFFERENCE; TRANSCRIPTION INITIATION SITE;

ALZHEIMER DISEASE; ANIMALS; APOLIPOPROTEINS E; BRAIN; BRAIN CHEMISTRY; CELL LINE, TUMOR; CELL LINEAGE; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICE; MICE, TRANSGENIC; MOLECULAR BIOLOGY; PC12 CELLS; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RATS; SEQUENCE HOMOLOGY, NUCLEIC ACID; SPECIES SPECIFICITY;

RODENTIA;

EID: 35248846473     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2007.04831.x     Document Type: Article

References (74)

1. Alves da Costa C., Sunyach C., Pardossi-Piquard R., Sevalle J., Vincent B., Boyer N., Kawarai T., Girardot N., St George-Hyslop P. Checler F. (2006) Presenilin-dependent gamma-secretase-mediated control of p53-associated cell death in Alzheimer's disease. J. Neurosci. 26, 6377 6385.
2. Artiga M. J., Bullido M. J., Frank A. et al. (1998a) Risk for Alzheimer's disease correlates with transcriptional activity of the APOE gene. Hum. Mol. Genet. 7, 1887 1892.
3. Artiga M. J., Bullido M. J., Sastre I., Recuero M., Garcia M. A., Aldudo J., Vazquez J. Valdivieso F. (1998b) Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene. FEBS Lett. 421, 105 108.
4. Baskin F., Smith G. M., Fosmire J. A. Rosenberg R. N. (1997) Altered apolipoprotein E secretion in cytokine treated human astrocyte cultures. J. Neurol. Sci. 148, 15 18.
5. Bois P. R. (2003) Hypermutable minisatellites, a human affair? Genomics 81, 349 355.
6. Brecht W. J., Harris F. M., Chang S. et al. (2004) Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J. Neurosci. 24, 2527 2534.
7. Brendza R. P., Bales K. R., Paul S. M. Holtzman D. M. (2002) Role of apoE/Abeta interactions in Alzheimer's disease: insights from transgenic mouse models. Mol. Psychiatry 7, 132 135.
8. Breslow J. L. (1996) Mouse models of atherosclerosis. Science 272, 685 688.
9. Bullido M. J., Artiga M. J., Recuero M. et al. (1998) A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia. Nat. Genet. 18, 69 71.
10. Chenna R., Sugawara H., Koike T., Lopez R., Gibson T. J., Higgins D. G. Thompson J. D. (2003) Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res. 31, 3497 3500.
11. Christensen K., Johnson T. E. Vaupel J. W. (2006) The quest for genetic determinants of human longevity: challenges and insights. Nat. Rev. Genet. 7, 436 448.
12. Cohen J. (2007) Relative differences: the myth of 1%. Science 316, 1836.
13. Cook C. N., Hejna M. J., Magnuson D. J. Lee J. M. (2005) Expression of calcipressin1, an inhibitor of the phosphatase calcineurin, is altered with aging and Alzheimer's disease. J. Alzheimers Dis. 8, 63 73.
14. Corder E. H., Saunders A. M., Strittmatter W. J., Schmechel D. E., Gaskell P. C., Small G. W., Roses A. D., Haines J. L. Pericak-Vance M. A. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921 923.
15. DeMattos R. B. (2004) Apolipoprotein E dose-dependent modulation of beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. J. Mol. Neurosci. 23, 255 262.
16. Du Y., Chen X., Wei X., Bales K. R., Berg D. T., Paul S. M., Farlow M. R., Maloney B., Ge Y.-W. Lahiri D. K. (2005) NF-kappaB mediates amyloid beta peptide-stimulated activity of the human apolipoprotein E gene promoter in human astroglial cells. Brain Res. Mol. Brain Res. 136, 177 188.
17. Evans D. A., Beckett L. A., Field T. S., Feng L., Albert M. S., Bennett D. A., Tycko B. Mayeux R. (1997) Apolipoprotein E epsilon4 and incidence of Alzheimer disease in a community population of older persons. JAMA 277, 822 824.
18. Evans R. M., Hui S., Perkins A., Lahiri D. K., Poirier J. Farlow M. R. (2004) Cholesterol and APOE genotype interact to influence Alzheimer disease progression. Neurology 62, 1869 1871.
19. Farlow M. R., Lahiri D. K., Poirier J., Davignon J. Hui S. (1996) Apolipoprotein E genotype and gender influence response to tacrine therapy. Ann. NY Acad. Sci. 802, 101 110.
20. Farlow M. R., Lahiri D. K., Poirier J., Davignon J., Schneider L. Hui S. L. (1998) Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease. Neurology 50, 669 677.
21. Fontemaggi G., Gurtner A., Damalas A., Costanzo A., Higashi Y., Sacchi A., Strano S., Piaggio G. Blandino G. (2005) deltaEF1 repressor controls selectively p53 family members during differentiation. Oncogene 24, 7273 7280.
22. Ge Y.-W. Lahiri D. K. (2002) Regulation of promoter activity of the APP gene by cytokines and growth factors: implications in Alzheimer's disease. Ann. NY Acad. Sci. 973, 463 467.
23. Ghosh C., Song W. Lahiri D. K. (2000) Efficient DNA transfection in neuronal and astrocytic cell lines. Mol. Biol. Rep. 27, 113 121.
24. Gómez-Nicola D., Doncel-Pérez E. Nieto-Sampedro M. (2006) Regulation by GD3 of the proinflammatory response of microglia mediated by interleukin-15. J. Neurosci. Res. 83, 754 762.
25. Gureje O., Ogunniyi A., Baiyewu O. et al. (2006) APOE epsilon4 is not associated with Alzheimer's disease in elderly Nigerians. Ann. Neurol. 59, 182 185.
26. Horiuchi K., Tajima S., Menju M. Yamamoto A. (1989) Structure and expression of mouse apolipoprotein E gene. J. Biochem. (Tokyo) 106, 98 103.
27. Horsley V. Pavlath G. K. (2002) NFAT: ubiquitous regulator of cell differentiation and adaptation. J. Cell Biol. 156, 771 774.
28. Houck C. M., Rinehart F. P. Schmid C. W. (1979) A ubiquitous family of repeated DNA sequences in the human genome. J. Mol. Biol. 132, 289 306.
29. Lahiri D. K. (1998) An region upstream of the gene promoter for the beta-amyloid precursor protein interacts with proteins from nuclear extracts of the human brain and PC12 cells. Brain Res. Mol. Brain Res. 58, 112 122.
30. Lahiri D. K. Maloney B. (2006) Genes are not our destiny: the somatic epitype bridges between the genotype and the phenotype. Nat Rev Neurosci 7:doi:
31. Lahiri D. K., Lewis S. Farlow M. R. (1994) Tacrine alters the secretion of the beta-amyloid precursor protein in cell lines. J. Neurosci. Res. 37, 777 787.
32. Lahiri D. K., Alley G. M., Ge Y. W. Du Y. (2002) Functional characterization of the 5′-regulatory region of the murine apolipoprotein gene. Ann. NY Acad. Sci. 973, 340 344.
33. Lahiri D. K., Ghosh C. Ge Y. W. (2003) A proximal gene promoter region for the beta-amyloid precursor protein provides a link between development, apoptosis, and Alzheimer's disease. Ann. NY Acad. Sci. 1010, 643 647.
34. Lahiri D. K., Sambamurti K. Bennett D. A. (2004) Apolipoprotein gene and its interaction with the environmentally driven risk factors: molecular, genetic and epidemiological studies of Alzheimer's disease. Neurobiol. Aging 25, 651 660.
35. Lahiri D. K., Maloney B., Basha M. R., Ge Y. W. Zawia N. H. (2007) How and when environmental agents and dietary factors affect the course of Alzheimer's disease: the 'LEARn' model (Latent Early Associated Regulation) may explain the triggering of AD. Curr. Alzheimer Res. 4, 219 228.
36. Lambert J. C., Berr C., Pasquier F. et al. (1998) Pronounced impact of Th1/E47cs mutation compared with -491 AT mutation on neural APOE gene expression and risk of developing Alzheimer's disease. Hum. Mol. Genet. 7, 1511 1516.
37. Lambert J. C., Araria-Goumidi L., Myllykangas L. et al. (2002) Contribution of APOE promoter polymorphisms to Alzheimer's disease risk. Neurology 59, 59 66.
38. Laws S. M., Clarnette R. M., Taddei K. et al. (2002) APOE-epsilon4 and APOE -491A polymorphisms in individuals with subjective memory loss. Mol. Psychiatry 7, 768 775.
39. van Leuven F. (2000) Single and multiple transgenic mice as models for Alzheimer's disease. Prog. Neurobiol. 61, 305 312.
40. Levy-Lahad E., Lahad A., Wijsman E. M., Bird T. D. Schellenberg G. D. (1995) Apolipoprotein E genotypes and age of onset in early-onset familial Alzheimer's disease. Ann. Neurol. 38, 678 680.
41. Loots G. G., Ovcharenko I., Pachter L., Dubchak I. Rubin E. M. (2002) rVista for comparative sequence-based discovery of functional transcription factor binding sites. Genome Res. 12, 832 839.
42. Luckow B. Schutz G. (1987) CAT constructions with multiple unique restriction sites for the functional analysis of eukaryotic promoters and regulatory elements. Nucleic Acids Res. 15, 5490.
43. Lynch J. R., Tang W., Wang H., Vitek M. P., Bennett E. R., Sullivan P. M., Warner D. S. Laskowitz D. T. (2003) APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response. J. Biol. Chem. 278, 48529 48533.
44. Masuda E. S., Naito Y., Tokumitsu H., Campbell D., Saito F., Hannum C., Arai K.-I. Arai N. (1995) NFATx, a novel member of the nuclear factor of activated T cells family that is expressed predominantly in the thymus. Mol. Cell. Biol. 15, 2697 2706.
45. Matys V., Kel-Margoulis O. V., Fricke E. et al. (2006) TRANSFAC and its module TRANSCompel: transcriptional gene regulation in eukaryotes. Nucleic Acids Res. 34, D108 D110.
46. Meir K. S. Leitersdorf E. (2004) Atherosclerosis in the apolipoprotein-E-deficient mouse: a decade of progress. Arterioscler. Thromb. Vasc. Biol. 24, 1006 1014.
47. Miller S. G., De Vos P., Guerre-Millo M., Wong K., Hermann T., Staels B., Briggs M. R. Auwerx J. (1996) The adipocyte specific transcription factor C/EBPalpha modulates human ob gene expression. Proc. Natl Acad. Sci. USA 93, 5507 5511.
48. Mui S., Briggs M., Chung H., Wallace R. B., Gomez-Isla T., Rebeck G. W. Hyman B. T. (1996) A newly identified polymorphism in the apolipoprotein E enhancer gene region is associated with Alzheimer's disease and strongly with the epsilon 4 allele. Neurology 47, 196 201.
49. Myers A. J. Goate A. M. (2001) The genetics of late-onset Alzheimer's disease. Curr. Opin. Neurol. 14, 433 440.
50. Nickerson D. A., Taylor S. L., Weiss K. M., Clark A. G., Hutchinson R. G., Stengard J., Salomaa V., Vartiainen E., Boerwinkle E. Sing C. F. (1998) DNA sequence diversity in a 9.7-kb region of the human lipoprotein lipase gene. Nat. Genet. 19, 233 240.
51. Nicodemus K. K., Stenger J. E., Schmechel D. E. et al. (2004) Comprehensive association analysis of APOE regulatory region polymorphisms in Alzheimer disease. Neurogenetics 5, 201 208.
52. Olaisen B., Teisberg P. Gedde-Dahl Jr. T. (1982) The locus for apolipoprotein E (apoE) is linked to the complement component C3 (C3) locus on chromosome 19 in man. Hum. Genet. 62, 233 236.
53. Pahnke J., Walker L. C., Schroeder E., Vogelgesang S., Stausske D., Walther R. Warzok R. W. (2003) Cerebral beta-amyloid deposition is augmented by the -491AA promoter polymorphism in non-demented elderly individuals bearing the apolipoprotein E epsilon4 allele. Acta Neuropathol (Berl) 105, 25 29.
54. Paik Y. K., Chang D. J., Reardon C. A., Davies G. E., Mahley R. W. Taylor J. M. (1985) Nucleotide sequence and structure of the human apolipoprotein E gene. Proc. Natl Acad. Sci. USA 82, 3445 3449.
55. Pajukanta P., Lilja H. E., Sinsheimer J. S. et al. (2004) Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1). Nat. Genet. 36, 371 376.
56. Poirier J., Delisle M. C., Quirion R. et al. (1995) Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc. Natl Acad. Sci. USA 92, 12260 12264.
57. Quandt K., Frech K., Karas H., Wingender E. Werner T. (1995) MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res. 23, 4878 4884.
58. Rajavashisth T. B., Kaptein J. S., Reue K. L. Lusis A. J. (1985) Evolution of apolipoprotein E: mouse sequence and evidence for an 11-nucleotide ancestral unit. Proc. Natl Acad. Sci. USA 82, 8085 8089.
59. Sambamurti K., Granholm A. C., Kindy M. S., Bhat N. R., Greig N. H., Lahiri D. K. Mintzer J. E. (2004) Cholesterol and Alzheimer's disease: clinical and experimental models suggest interactions of different genetic, dietary and environmental risk factors. Curr. Drug Targets 5, 517 528.
60. Schmechel D. E., Saunders A. M., Strittmatter W. J., Crain B. J., Hulette C. M., Joo S. H., Pericak-Vance M. A., Goldgaber D. Roses A. D. (1993) Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc. Natl Acad. Sci. USA 90, 9649 9653.
61. Schug J. Overton G. C. (1998) TESS: Transcription Element Search Software on the WWW, in Technical Reports of the Computational Biology and Informatics Laboratory, School of Medicine, University of Pennsylvania, pp. 1 10. University of Pennsylvania, Philadelphia PA
62. Shaulian E. Karin M. (2002) AP-1 as a regulator of cell life and death. Nat. Cell Biol. 4, E131 E136.
63. Singh N. N. Ramji D. P. (2006) Transforming growth factor-beta-induced expression of the apolipoprotein E gene requires c-Jun N-terminal kinase, p38 kinase, and casein kinase 2. Arterioscler. Thromb. Vasc. Biol. 26, 1323 1329.
64. Smit A. F. Riggs A. D. (1995) MIRs are classic, tRNA-derived SINEs that amplified before the mammalian radiation. Nucleic Acids Res. 23, 98 102.
65. Sullivan P. M., Mace B. E., Maeda N. Schmechel D. E. (2004) Marked regional differences of brain human apolipoprotein E expression in targeted replacement mice. Neuroscience 124, 725 733.
66. Sun Y., Wu S., Bu G., Onifade M. K., Patel S. N., LaDu M. J., Fagan A. M. Holtzman D. M. (1998) Glial fibrillary acidic protein-apolipoprotein E (apoE) transgenic mice: astrocyte-specific expression and differing biological effects of astrocyte-secreted apoE3 and apoE4 lipoproteins. J. Neurosci. 18, 3261 3272.
67. Uchihara T., Duyckaerts C., He Y., Kobayashi K., Seilhean D., Amouyel P. Hauw J. J. (1995) ApoE immunoreactivity and microglial cells in Alzheimer's disease brain. Neurosci. Lett. 195, 5 8.
68. Wang J. C., Kwon J. M., Shah P., Morris J. C. Goate A. (2000) Effect of APOE genotype and promoter polymorphism on risk of Alzheimer's disease. Neurology 55, 1644 1649.
69. Wang H., Xing J., Grover D., Hedges D. J., Han K., Walker J. A. Batzer M. A. (2005) SVA elements: a hominid-specific retroposon family. J. Mol. Biol. 354, 994 1007.
70. Xu Q., Bernardo A., Walker D., Kanegawa T., Mahley R. W. Huang Y. (2006) Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. J. Neurosci. 26, 4985 4994.
71. Yamagata K., Urakami K., Ikeda K., Ji Y., Adachi Y., Arai H., Sasaki H., Sato K. Nakashima K. (2001) High expression of apolipoprotein E mRNA in the brains with sporadic Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 12, 57 62.
72. Yen G., Croci A., Dowling A., Zhang S., Zoeller R. T. Darling D. S. (2001) Developmental and functional evidence of a role for Zfhep in neural cell development. Brain Res. Mol. Brain Res. 96, 59 67.
73. Zannis V. I., Kan H. Y., Kritis A., Zanni E. Kardassis D. (2001) Transcriptional regulation of the human apolipoprotein genes. Front. Biosci. 6, D456 D504.
74. Zarow C. Victoroff J. (1998) Increased apolipoprotein E mRNA in the hippocampus in Alzheimer disease and in rats after entorhinal cortex lesioning. Exp. Neurol. 149, 79 86.